Regeneron Expands Bispecifics, Gene Therapy Programs As Exec Hints At More Deals

The drug maker reported what it said were encouraging early uptake signs for Eylea HD while also seeking to reassure analysts concerned about its BCMA-directed bispecific’s differentiation.